{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:29:07Z","timestamp":1770715747492,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s13555-021-00539-3","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T16:02:41Z","timestamp":1621612961000},"page":"1085-1106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience"],"prefix":"10.1007","volume":"11","author":[{"given":"Larisa J.","family":"Geskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"539_CR1","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","volume":"88","author":"E Diamandidou","year":"1996","unstructured":"Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood. 1996;88:2385\u2013409.","journal-title":"Blood"},{"key":"539_CR2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","volume":"136","author":"R van Doorn","year":"2000","unstructured":"van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136:504\u201310.","journal-title":"Arch Dermatol"},{"key":"539_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/cco.2018.11.03","volume":"8","author":"ML Lovgren","year":"2019","unstructured":"Lovgren ML, Scarisbrick JJ. Update on skin directed therapies in mycosis fungoides. Chin Clin Oncol. 2019;8:7.","journal-title":"Chin Clin Oncol"},{"key":"539_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","volume":"40","author":"HS Zackheim","year":"1999","unstructured":"Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol. 1999;40:418\u201325.","journal-title":"J Am Acad Dermatol"},{"key":"539_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1200\/JCO.2001.19.3.779","volume":"19","author":"EC de Coninck","year":"2001","unstructured":"de Coninck EC, Kim YH, Varghese A, Hoppe RT. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol. 2001;19:779\u201384.","journal-title":"J Clin Oncol"},{"key":"539_CR6","first-page":"857","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857\u201366.","journal-title":"Arch Dermatol"},{"key":"539_CR7","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33:3766\u201373.","journal-title":"J Clin Oncol"},{"key":"539_CR8","first-page":"220","volume":"7","author":"GI Al Hothali","year":"2013","unstructured":"Al Hothali GI. Review of the treatment of mycosis fungoides and S\u00e9zary syndrome: a stage-based approach. Int J Health Sci (Qassim). 2013;7:220\u201339.","journal-title":"Int J Health Sci (Qassim)"},{"key":"539_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/CCO.0000000000000161","volume":"27","author":"JA DeSimone","year":"2015","unstructured":"DeSimone JA, Sodha P, Ignatova D, Dummer R, Cozzio A, Guenova E. Recent advances in primary cutaneous T-cell lymphoma. Curr Opin Oncol. 2015;27:128\u201333.","journal-title":"Curr Opin Oncol"},{"key":"539_CR10","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv30\u201340.","journal-title":"Ann Oncol."},{"key":"539_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"key":"539_CR12","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines (NCCN Guidelines\u00ae). Primary cutaneous lymphomas. Version 2.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf. Accessed 1 Feb 2021."},{"key":"539_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.17240","volume":"180","author":"D Gilson","year":"2019","unstructured":"Gilson D, Whittaker SJ, Child FJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180:496\u2013526.","journal-title":"Br J Dermatol"},{"key":"539_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archderm.134.8.949","volume":"134","author":"HS Zackheim","year":"1998","unstructured":"Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998;134:949\u201354.","journal-title":"Arch Dermatol"},{"key":"539_CR15","doi-asserted-by":"crossref","unstructured":"Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149:25\u201332.","DOI":"10.1001\/2013.jamadermatol.541"},{"key":"539_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archderm.138.3.325","volume":"138","author":"D Breneman","year":"2002","unstructured":"Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138:325\u201332.","journal-title":"Arch Dermatol"},{"key":"539_CR17","doi-asserted-by":"crossref","unstructured":"Kim YH, Duvic M, Guitart J, Lessin SR. Tolerability and efficacy of mechlorethamine 0.04% gel in CTCL (mycosis fungoides) after initial treatment with topical mechlorethamine 0.02% gel. Presented at: 6th Annual T-cell Lymphoma Forum; January 23\u201325, 2014; San Francisco, CA, USA.","DOI":"10.1200\/jco.2014.32.15_suppl.9093"},{"key":"539_CR18","unstructured":"Ledaga [summary of product characteristics]. London, UK: Actelion Registration Ltd; 2017."},{"key":"539_CR19","unstructured":"ATU Rapport de Synthese pour Valchlor\/Ledaga\u00ae. Rapport nr. 9, version 1.0. Helsinn Birex Pharmaceuticals Ltd. Dublin, Ireland. 2019."},{"key":"539_CR20","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1208\/s12249-018-1196-8","volume":"19","author":"DW Osborne","year":"2018","unstructured":"Osborne DW, Musakhanian J. Skin penetration and permeation properties of Transcutol\u00ae-neat or diluted mixtures. AAPS PharmSciTech. 2018;19:3512\u201333.","journal-title":"AAPS PharmSciTech"},{"key":"539_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijpharm.2008.06.016","volume":"362","author":"WA Ritschel","year":"2008","unstructured":"Ritschel WA, Ye W, Buhse L, Reepmeyer JC. Stability of the nitrogen mustard mechlorethamine in novel formulations for dermatological use. Int J Pharm. 2008;362:67\u201373.","journal-title":"Int J Pharm"},{"key":"539_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.fct.2014.06.028","volume":"72","author":"DW Sullivan Jr","year":"2014","unstructured":"Sullivan DW Jr, Gad SC, Julien M. A review of the nonclinical safety of Transcutol\u00ae, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient. Food Chem Toxicol. 2014;72:40\u201350.","journal-title":"Food Chem Toxicol"},{"key":"539_CR23","unstructured":"Ashland Inc. Klucel\u2122 hydroxypropylcellulose. Physical and chemical properties. 2017. https:\/\/www.ashland.com\/file_source\/Ashland\/Product\/Documents\/Pharmaceutical\/PC_11229_Klucel_HPC.pdf. Accessed 1 Feb 2021."},{"key":"539_CR24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2174\/1568026616666160930131737","volume":"17","author":"VWC Soo","year":"2017","unstructured":"Soo VWC, Kwan BW, Quezada H, et al. Repurposing of anticancer drugs for the treatment of bacterial infections. Curr Top Med Chem. 2017;17:1157\u201376.","journal-title":"Curr Top Med Chem"},{"issue":"155\u20137","key":"539_CR25","first-page":"160","volume":"25","author":"L Molin","year":"1980","unstructured":"Molin L, Thomsen K, Volden G, et al. Aspects of the treatment of mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Study Group. Cutis. 1980;25(155\u20137):160\u20131.","journal-title":"Cutis"},{"key":"539_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","volume":"20","author":"EC Vonderheid","year":"1989","unstructured":"Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20:416\u201328.","journal-title":"J Am Acad Dermatol"},{"key":"539_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","volume":"27","author":"LM Lindahl","year":"2013","unstructured":"Lindahl LM, Fenger-Gron M, Iversen L. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis. J Eur Acad Dermatol Venereol. 2013;27:163\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"539_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21037\/cco.2018.10.01","volume":"8","author":"T Jennings","year":"2019","unstructured":"Jennings T, Duffy R, Gochoco A, et al. Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment. Chin Clin Oncol. 2019;8:13.","journal-title":"Chin Clin Oncol"},{"key":"539_CR29","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1002\/1097-0142(197712)40:6<2851::AID-CNCR2820400615>3.0.CO;2-X","volume":"40","author":"NM Price","year":"1977","unstructured":"Price NM, Hoppe RT, Constantine VS, Fuks ZY, Farber EM. The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy. Cancer. 1977;40:2851\u20133.","journal-title":"Cancer"},{"key":"539_CR30","first-page":"681","volume":"63","author":"EC Vonderheid","year":"1979","unstructured":"Vonderheid EC, Van Scott EJ, Wallner PE, Johnson WC. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat Rep. 1979;63:681\u20139.","journal-title":"Cancer Treat Rep"},{"key":"539_CR31","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/1097-0142(19831215)52:12<2214::AID-CNCR2820521207>3.0.CO;2-H","volume":"52","author":"NM Price","year":"1983","unstructured":"Price NM, Hoppe RT, Deneau DG. Ointment-based mechlorethamine treatment for mycosis fungoides. Cancer. 1983;52:2214\u20139.","journal-title":"Cancer"},{"key":"539_CR32","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/archderm.1984.01650480047016","volume":"120","author":"DL Ramsay","year":"1984","unstructured":"Ramsay DL, Parnes RE, Dubin N. Response of mycosis fungoides to topical chemotherapy with mechlorethamine. Arch Dermatol. 1984;120:1585\u201390.","journal-title":"Arch Dermatol"},{"key":"539_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2340\/00015555655358","volume":"65","author":"H Zachariae","year":"1985","unstructured":"Zachariae H, Thestrup-Pedersen K, S\u00f8gaard H. Topical nitrogen mustard in early mycosis fungoides. A 12-year experience. Acta Derm Venereol. 1985;65:53\u20138.","journal-title":"Acta Derm Venereol."},{"key":"539_CR34","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","volume":"5","author":"RT Hoppe","year":"1987","unstructured":"Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol. 1987;5:1796\u2013803.","journal-title":"J Clin Oncol"},{"key":"539_CR35","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","volume":"19","author":"DL Ramsay","year":"1988","unstructured":"Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol. 1988;19:684\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"539_CR36","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1046\/j.1365-2133.2002.04802.x","volume":"147","author":"P Foulc","year":"2002","unstructured":"Foulc P, Evrard V, Dalac S, et al. Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment. Br J Dermatol. 2002;147:926\u201330.","journal-title":"Br J Dermatol"},{"key":"539_CR37","first-page":"165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139:165\u201373.","journal-title":"Arch Dermatol"},{"key":"539_CR38","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/archderm.141.9.1117","volume":"141","author":"J de Quatrebarbes","year":"2005","unstructured":"de Quatrebarbes J, Est\u00e8ve E, Bagot M, et al. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol. 2005;141:1117\u201320.","journal-title":"Arch Dermatol"},{"key":"539_CR39","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/archderm.1995.01690160060009","volume":"131","author":"AG Licata","year":"1995","unstructured":"Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. Arch Dermatol. 1995;131:432\u20135.","journal-title":"Arch Dermatol."},{"key":"539_CR40","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/archderm.135.11.1349","volume":"135","author":"E Est\u00e8ve","year":"1999","unstructured":"Est\u00e8ve E, Bagot M, Joly P, et al. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol. 1999;135:1349\u201353.","journal-title":"Arch Dermatol."},{"key":"539_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjd.12620","volume":"170","author":"LM Lindahl","year":"2014","unstructured":"Lindahl LM, Fenger-Gr\u00f8n M, Iversen L. Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study. Br J Dermatol. 2014;170:699\u2013704.","journal-title":"Br J Dermatol"},{"key":"539_CR42","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jaad.2019.12.070","volume":"83","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, Geskin L, Guitart J, et al. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: preliminary findings from a prospective observational study. J Am Acad Dermatol. 2020;83:928\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"539_CR43","unstructured":"Gilmore ES, Alexander-Savino CV, Chung CG, Poligone B. Incidence and types of contact dermatitis after chlormethine gel treatment in patients with mycosis fungoides-type cutaneous T-cell lymphoma: The MIDAS study. Presented at the 4th World Congress of Cutaneous Lymphomas. 12\u201314 February 2020; Barcelona, Spain. Abstract Y-04. Available at http:\/\/wcclbarcelona2020.com\/images\/site\/PROTEGIDO\/Abstracts_WCCl_2020_DIGITAL.pdf. Accessed 1 Feb 2021."},{"key":"539_CR44","unstructured":"Alexander-Savino CV, Chung CG, Gilmore ES, Poligone B. Molecular signature patterns related to the development of contact dermatitis in patients with mycosis fungoides-type cutaneous T-cell lymphoma treated with chlormethine gel. Presented at the 4th World Congress of Cutaneous Lymphomas. 12\u201314 February 2020; Barcelona, Spain. Abstract 026. Available at http:\/\/wcclbarcelona2020.com\/images\/site\/PROTEGIDO\/Abstracts_WCCl_2020_DIGITAL.pdf. Accessed 1 Feb 2021."},{"key":"539_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00591-x","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021. https:\/\/doi.org\/10.1007\/s40257-021-00591-x.","journal-title":"Am J Clin Dermatol."},{"key":"539_CR46","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1046\/j.1523-1747.1998.00206.x","volume":"110","author":"EC Vonderheid","year":"1998","unstructured":"Vonderheid EC, Ekbote SK, Kerrigan K, et al. The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma. J Invest Dermatol. 1998;110:946\u201350.","journal-title":"J Invest Dermatol"},{"key":"539_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/mmt-2016-0022","volume":"4","author":"MM Johnson","year":"2017","unstructured":"Johnson MM, Leachman SA, Aspinwall LG, et al. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag. 2017;4:13\u201337.","journal-title":"Melanoma Manag"},{"key":"539_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2133.1978.tb01962.x","volume":"99","author":"A Du Vivier","year":"1978","unstructured":"Du Vivier A, Vonderheid EC, Van Scott EJ, Urbach F. Mycosis fungoides, nitrogen mustard and skin cancer. Br J Dermatol. 1978;99:61\u20133.","journal-title":"Br J Dermatol"},{"key":"539_CR49","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/1346-8138.15276","volume":"47","author":"MH Trager","year":"2020","unstructured":"Trager MH, Chen C, Husain S, Geskin LJ. Nitrogen mustard gel-induced inflammation triggers lymphomatoid papulosis in patients with mycosis fungoides. J Dermatol. 2020;47:546\u201350.","journal-title":"J Dermatol"},{"key":"539_CR50","first-page":"22","volume":"2","author":"JA Latkowski","year":"2009","unstructured":"Latkowski JA, Heald P. Strategies for treating cutaneous T-cell lymphoma: part 1: remission. J Clin Aesthet Dermatol. 2009;2:22\u20137.","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00539-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:52:32Z","timestamp":1699059152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00539-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00539-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u201cA peer-reviewed infographic was retrospectively added to this publication.\u201d","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}